Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

Last updated: April 14, 2011
Sponsor: Palau Pharma S.A.
Overall Status: Completed

Phase

2

Condition

Rhinitis, Allergic, Perennial

Allergy

Common Cold

Treatment

N/A

Clinical Study ID

NCT01260753
PPh/00071/10
2010-021858-20
  • Ages 18-55
  • Male
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to explore the activity of UR-63325 in a model of allergic rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise healthy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of written informed consent to participate (prior to any study-relatedprocedures being performed) as shown by a signature on the volunteer consent form andto be able to adhere to the study restrictions and examination schedule

  • Subjects with confirmed history of seasonal allergic rhinitis to grass pollen (bydirect questioning of presence of positive skin prick test to pollen and History ofSymptoms of allergic rhinitis) within the previous two years

  • Positive skin prick test to timothy grass pollen (wheal difference with negativecontrol ≥ 3 mm) at screening

  • Subjects with positive response to screening nasal challenge with increasing doses oftimothy grass pollen (Symptoms worsening with respect to the response to the diluentchallenge of ≥4 points in the total nasal symptom score [TNSS]) within one hour afterlast nasal allergen challenge

  • Screening and baseline FEV1 >80% predicted and FEV1/FVC > 70% predicted

Exclusion

Exclusion Criteria:

  • Symptoms of allergic rhinitis within 2 weeks prior to screening

  • Upper respiratory infection or sinusitis within 14 days of screening and also within 14 days of study start in each of the two periods

  • Structural nasal abnormalities or nasal polyps on examination, a history of nosebleeding or recent nasal surgery

  • History of asthma or asthmatic symptoms or other respiratory disease other thanrhinitis within the last 2 years or FEV1<80% of predicted at screening or baseline

Study Design

Total Participants: 24
Study Start date:
December 01, 2010
Estimated Completion Date:
March 31, 2011

Connect with a study center

  • Parexel International GmbH

    Berlin, 14050
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.